ArticleThe journal of obstetrics and gynaecology research2025

A potential inflammatory biomarker for advanced endometrial cancer treated with lenvatinib plus pembrolizumab.

Shintaro Yanazume et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.